# EDGAR Filing Document

**Accession Number:** 0001095981
**File Stem:** 0001193125-25-142216
**Filing Date:** 2025-6
**Character Count:** 2346
**Document Hash:** 664ad9075c4264a5f6772ec0e02b6baa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-142216.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001193125-25-142216

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001095981
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330827593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756
- **BUSINESS PHONE:** 737.255.7194

**MAIL ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTORI THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MACROPORE INC
- **DATE OF NAME CHANGE:** 20010320

June 17, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Plus Therapeutics, Inc.**  |

---

**Registration Statement on Form S-1 submitted for filing on June 17, 2025** <br>

**File No. 333-** <br>

**Request for Acceleration of Effective Date** <br>

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement on Form S-1, as amended (the "<u>Registration Statement</u>"), so that it becomes effective as of 9:00 a.m. Eastern Time on Monday, June 23, 2025, or as soon thereafter as possible.

*[Signature Page to Follow]* 

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **Plus Therapeutics, Inc.** | **Plus Therapeutics, Inc.** |
| By: | /s/ Andrew Sims |
| Name: | Andrew Sims |
| Title: | Chief Financial Officer |

---

cc: Aaron M. Schleicher, Sullivan & Worcester LLP

*[Signature Page to Acceleration Request]*